Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 7
Encontrada(s) 1 página(s)

RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Systematic review on genetic polymorphisms associated with idiosyncratic drug-induced liver injury (iDILI): iDILInet as an interactive visualization tool

  • Matilla-Cabello, Gonzalo
  • Remesal-Doblado, Ángela
  • Celebi-Cinar, Muzzez
  • Bodoque-García, Ana
  • Betul Metin, Fatma
  • Rezaei, Aida
  • Aftab, Moiz
  • De los Santos-Fernández, Romina
  • Segovia-Zafra, Antonio
  • Álvarez-Álvarez, Ismael
  • Andrade-Bellido, Raúl Jesús
  • Cakan-Akdogan, Gulcin
  • Lucena-González, María Isabel
  • Konu, Ozlen
  • Villanueva-Paz, Marina
Idiosyncratic drug-induced liver injury (iDILI) is a rare, dose-independent and unpredictable adverse reaction occurring at therapeutic drug exposure, and it presents a significant challenge for drug development and patient safety. Despite extensive research, genetic susceptibility to iDILI remains poorly understood. We conducted a comprehensive systematic study of 139 human genetic studies to identify and characterize genetic polymorphisms associated with increased risk or protection against iDILI. Our study included candidate gene studies and genome-wide association studies (GWAS), encompassing 83 risk and 25 protective genes, with NAT2, HLA-B, and SLCO1B1 among the most frequently reported. We performed functional enrichment analyses using KEGG and Gene Ontology, revealing key biological pathways related to immune response, xenobiotic metabolism, and bile secretion. To enhance data accessibility and interpretation, we developed iDILInet, a publicly available web application that enables interactive exploration and network-based visualization of iDILI-associated gene-variant-drug relationships, enriched with liver-specific expression data from the Human Protein Atlas (HPA). Our work provides a novel integrative resource that supports ongoing efforts in precision medicine and pharmacogenomics and represents a significant advancement in implementing living systematic reviews in toxicogenomics., Consejería de Salud de Andalucía, Instituto de Salud Carlos III, Fondo Europeo de Desarrollo Regional, Agencia Española del Medicamento y Productos Sanitarios, Ministerio de Ciencia, Innovación y Universidades, Agencia Estatal de Investigación, Universidad de Málaga
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

Epigenetic modifications in drug-induced liver injury: A systematic review

  • de los Santos-Fernández, Romina Lorena
  • Segovia-Zafra, Antonio
  • Paz-López, Guillermo
  • Matilla-Cabello, Gonzalo
  • Niu, Hao
  • Álvarez-Álvarez, Ismael
  • Stephens, Camilla
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • Medina-Cáliz, Inmaculada
Genetic susceptibility has been identified in idiosyncratic drug-induced liver injury, a potentially severe adverse reaction towards drugs, herbal products and dietary supplements. However, its occurrence cannot be fully explained by the presence of genetic variants in specific genes, suggesting that other factors are involved. Druginduced liver injury epigenetic signatures could help explain genetic regulatory mechanisms behind this disease and might provide disease biomarkers. This systematic review aims to analyse all available information on epigenetic risk association studies in drug-induced liver injury. The main inclusion criterion was population studies on idiosyncratic drug-induced liver injury with significant risk association analysis between drug-induced liver injury and an epigenetic regulation mechanism. Out of the 7 included articles, 6 focused on DNA methylation and 1 on long noncoding RNA. All of the studies were on antituberculosis drug-induced liver injury and came from Asia. CpG site methylation in the CYP2D6 (odds ratio: 9.19, 95% confidence interval: 3.26–25.89, P < .001) and NAT2 (odds ratio: 8.37, 95% confidence interval: 2.39–29.32, P = .001) promoters conferred the highest risk. Hypomethylation of LINE-1 and Alu transposable elements has potential as antituberculosis drug-induced liver injury biomarkers, showing an area under the curve value of 0.94. To conclude, the studies mainly focused on DNA methylation modifications associated with antituberculosis drug-induced liver injury, with all of them coming from Asia, where tuberculosis is a public health burden. Despite the lack of knowledge in this area, the evidence has shown that DNA methylation alterations in antituberculosis drug-induced liver injury could have potential as a new diagnostic and therapeutic target., Instituto de Salud Carlos III, Agencia Estatal de Investigación, CIBER, European Comission
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

An Exploratory Study on the Pathogenic Role of Faecal Extracellular Vesicles in Metabolic Dysfunction-Associated Steatotic Liver Disease Progression and in Drug-Induced Liver Injury

  • Ruiz-Malagón, Antonio J.
  • Herraiz-Vilela, Marina
  • Pinazo-Bandera, José
  • Toro-Ortiz, Juan Pedro
  • López-Gómez, Carlos
  • Ho-Plagaro, Ailec
  • Garrido-Sánchez, Lourdes
  • Robles-Díaz, María Mercedes
  • Taminiau, Bernard
  • Daube, Georges
  • Sanabria-Cabrera, Judith
  • Matilla-Cabello, Gonzalo
  • Lucena-González, María Isabel
  • Andrade-Bellido, Raúl Jesús
  • García-Fuentes, Eduardo
  • García-Cortés, Miren
  • Rodríguez-Díaz, Cristina
The role of extracellular vesicles secreted by the gut microbiota present in faeces (fEVs) is not well known in metabolic dysfunction- associated steatotic liver disease (MASLD) and idiosyncratic drug-induced liver injury (DILI). We identify the microbiome profiles of fEVs in these liver diseases, and analyse the effects of fEVs from MASLD, without (F ≤ 2) or with (F ≥ 3) significant liver fibrosis, and DILI patients on inflammation, steatosis and mitochondrial function. DILI patients showed a consistent pattern in fEVs, characterised by a decrease in Paraprevotella and an increase in AAP99, Acinetobacter, Actinobacillus, Aerococcus and Anaeroglobus . A higher presence of 16S rDNA was observed in plasma EVs from MASLD and DILI patients. HepG2 cells treated with DILI and MASLD F ≥ 3 fEVs increased TLR4 , TLR5 , IL6 and CASP3 expression, and accumulation of lipid droplets. DILI fEVs enhanced the hepatotoxic impact of diclofenac on the response to microbial components ( TLR4 , TLR5 ), inflammatory response ( IL1B , IL6 ), accumulation of lipid droplets and mitochondrial dysfunction ( OPA1 , DNM1L ). In conclusion, bacterial EVs enter the bloodstream and could modulate the immune response. DILI and MASLD F ≥ 3 fEVs are drivers of the pro-inflammatory response and hepatocyte steatosis. DILI fEVs have a distinct bacterial profile that enhances the hepatotoxic potential of diclofenac., Instituto de Salud Carlos III, Consejería de Economía, Conocimiento, Empresas y Universidad, Junta de Andalucía, Consejería de Salud, Junta de Andalucía, European Comission, Ministerio de Ciencia, Innovación y Universidades
RIUMA. Repositorio Institucional de la Universidad de Málaga
Publicación Artículo científico (JournalArticle)

DILI Differences and Similarities between the US and Europe

  • Toro-Ortiz, Juan Pedro
  • Andrade-Bellido, Raúl Jesús
  • Pinazo-Bandera, José
Purpose of review To evaluate the critical role of international registries in understanding idiosyncratic drug-induced liver injury (DILI) by comparing clinical and epidemiological data from the Spanish DILI Registry, the Pro-Euro DILI registry, and the US DILIN. Recent findings Although amoxicillin-clavulanic acid remains the leading global DILI trigger, DILI cases in the US show higher severity and more herbal supplement involvement. Immune checkpoint inhibitors present new toxicity phenotypes. Registry collaborations have yielded advanced prognostic tools like the nR criteria for predicting liver failure, and RECAM, a novel electronic causality assessment scale offering greater diagnostic precision than RUCAM. Summary Registries are crucial for identifying rare DILI events that are missed by clinical trials, as well as for highlighting regional differences in triggers and outcomes. These networks are essential for identifying diagnostic biomarkers, and their findings benefit not only clinicians, but also regulators. Future research should prioritize the global validation of RECAM and utilize multinational biobanks to identify genetic risk factors, ultimately improving drug safety., Funding for open access charge: Universidad de Málaga / CBUA, Instituto de Salud Carlos III, European Union, Agencia Española de Medicamentos y Productos Sanitarios
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Membrane Vesicles of Toxigenic Clostridioides difficile Affect the Metabolism of Liver HepG2 Cells

  • Caballano-Infantes, Estefanía
  • Ho-Plagaro, Ailec
  • López-Gómez, Carlos
  • Martín-Reyes, Flores
  • Rodríguez-Pacheco, Francisca
  • Taminiau, Bernard
  • Daube, Georges
  • Garrido-Sánchez, Lourdes
  • Alcaín-Martínez, Guillermo
  • Andrade, Raúl J.
  • García-Cortés, Miren
  • Lucena, M. Isabel
  • García-Fuentes, Eduardo
  • Rodríguez-Díaz, Cristina
Clostridioides difficile infection (CDI) appears to be associated with different liver diseases. C. difficile secretes membrane vesicles (MVs), which may be involved in the development of nonalcoholic fatty liver disease (NALFD) and drug-induced liver injury (DILI). In this study, we investigated the presence of C. difficile-derived MVs in patients with and without CDI, and analyzed their effects on pathways related to NAFLD and DILI in HepG2 cells. Fecal extracellular vesicles from CDI patients showed an increase of Clostridioides MVs. C. difficile-derived MVs that were internalized by HepG2 cells. Toxigenic C. difficile-derived MVs decreased mitochondrial membrane potential and increased intracellular ROS compared to non-toxigenic C. difficile-derived MVs. In addition, toxigenic C. difficile-derived MVs upregulated the expression of genes related to mitochondrial fission (FIS1 and DRP1), antioxidant status (GPX1), apoptosis (CASP3), glycolysis (HK2, PDK1, LDHA and PKM2) and β-oxidation (CPT1A), as well as anti- and pro-inflammatory genes (IL-6 and IL-10). However, non-toxigenic C. difficile-derived MVs did not produce changes in the expression of these genes, except for CPT1A, which was also increased. In conclusion, the metabolic and mitochondrial changes produced by MVs obtained from toxigenic C. difficile present in CDI feces are common pathophysiological features observed in the NAFLD spectrum and DILI., This work was supported in part by a grant from the Instituto de Salud Carlos III (Spain) (PI18/01652, PI19/00883 and PI21/01248), and from the Consejería de Economía, Conocimiento, Empresas y Universidad (Junta de Andalucía, Spain) (PI18-RT-3364 and UMA18-FEDERJA-194). This study has been co-funded by FEDER funds (“A way to make Europe”) (“Andalucía se mueve con Europa”). CRD is supported by a grant from the Consejería de Transformación Económica, Industria, Conocimiento y Universidades de Junta de Andalucía (Spain) (DOC_01610). FMR is supported by a grant from the ISCIII (Spain) (FI19/00189). CLG is supported by a grant from the ISCIII (CP22/00050) (Spain). FRP is supported by the Miguel Servet program from the ISCIII (Spain) (CP18/00042). LGS is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (C-0028-2018). EGF is supported by the Nicolas Monardes program from the Consejería de Salud de Andalucía (Spain) (RC-0005-2020)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet

  • Lucena, M. Isabel
  • Villanueva-Paz, M.
  • Álvarez-Álvarez, I.
  • Aithal, G. P.
  • Björnsson, E. S.
  • Cakan-Akdogan, G.
  • Cubero, Francisco Javier
  • Esteves, F.
  • Falcón-Pérez, Juan M.
  • Fromenty, B.
  • García-Ruiz, Carmen
  • Grove, J. I.
  • Konu, O.
  • Kranendonk, M.
  • Kullak-Ublick, G. A.
  • Miranda, Joana
  • Remesal-Doblado, A.
  • Sancho-Bru, P.
  • Nelson, L.
  • Andrade, Raúl J.
  • Daly, A. K.
  • Fernández-Checa, José C.
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., The present study has been supported by grants from Instituto de Salud Carlos III (ISCIII) (contract numbers: PID2022–140169OB-C21; PI21/01248; PI19/00883) and from Consejería de Salud de Andalucía (contract number: PEMP-0127–2020, Spain), cofounded by the European Union. This research was funded by HORIZON-HLTH-2022-STAYHLTH-02, grant number 101095679. Funded by the European Union. Views and opinions expressed are however those of the authors only and do not necessarily reflect those of the European Union. Neither the European Union nor the granting authority can be held responsible for them. MK was partially supported by Grant UID/BIM/0009/2020 of the Portuguese Fundação para a Ciência e a Tecnologia (FCT). MVP and IAA hold Sara Borrell research contracts from ISCIII (CD21/00198 and CD20/00083, respectively). This research was supported by CIBERehd – Consorcio Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Instituto de Salud Carlos III, Ministerio de Ciencia e Innovación and Unión Europea – European Regional Development Fund. JIG and GPA are supported by NIHR Nottingham Biomedical Research Centre [NIHR203310]. The views expressed are those of the authors and not necessarily those of the National Health Service (NHS), the NIHR or the Department of Health. This publication is based upon work from COST Action “CA17112—Prospective European Drug-Induced Liver Injury Network” supported by COST (European Cooperation in Science and Technology); www.cost.eu., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Characterization of drug-induced liver injury associated with drug reaction with eosinophilia and systemic symptoms in two prospective DILI registries

  • Medina-Cáliz, Inmaculada|||0000-0003-0471-6658
  • Sanabria-Cabrera, Judith|||0000-0002-7769-7008
  • Villanueva-Paz, Marina|||0000-0003-4728-201X
  • Aukštikalnė, Lauryna
  • Stephens, Camilla|||0000-0002-0796-9610
  • Robles Díaz, Mercedes|||0000-0002-2365-2787
  • Pinazo-Bandera, José M.
  • García-Cortes, Miren
  • Conde, Isabel|||0000-0001-7863-2233
  • Soriano, German|||0000-0002-9267-6811
  • Bessone, Fernando
  • Hernandez, Nelia
  • Nunes, Vinicius
  • Paraná, Raymundo
  • Lucena, M. Isabel|||0000-0001-9586-4896
  • Andrade, Raúl J.
  • Niu, Hao
  • Alvarez-Alvarez, Ismael
Idiosyncratic drug-induced liver injury (DILI) associated with drug reactions with eosinophilia and systemic symptoms (DRESS) is poorly characterized among patients of Western countries. We aimed to comprehensively assess the clinical characteristics, outcomes, and causative agents in a prospective, well-vetted cohort of DILI patients with DRESS (DILI-DRESS). We identified 53 DILI-DRESS cases from the Spanish DILI Registry and the Latin American DILI Network. For comparison purposes, we defined a group of DILI patients (n = 881). DILI-DRESS cases were younger (47 vs. 53 years, respectively; p = 0.042) and presented more frequently with cholestatic/mixed damage (p = 0.018). Most DILI-DRESS patients showed moderate liver injury, 13% developed severe damage, and only one patient (with hepatocellular injury due to anti-tuberculosis drugs) progressed to acute liver failure and died. DILI-DRESS cases showed a distinctive causative drug pattern compared to DILI cases. The most frequent drugs were carbamazepine (13%), anti-tuberculosis drugs (13%), amoxicillin-clavulanate (11%), and allopurinol and lamotrigine (7.6% each). Among all cases of DILI due to allopurinol and lamotrigine, 67% presented with a DILI-DRESS phenotype, respectively. Higher total bilirubin (TBL) levels at DILI recognition (odds ratio [OR] 1.23; 95% confidence interval [CI] 1.04-1.45) and absence of eosinophilia (OR 8.77; 95% CI 1.11-69.20) increased the risk for developing a severe-fatal injury in DILI-DRESS patients. DILI-DRESS patients have a more frequent cholestasis/mixed pattern of injury at presentation, with antiepileptics as distinctive causative drug class. Most of the lamotrigine and allopurinol cases present with this phenotype. Higher TBL levels and absence of eosinophilia at DILI recognition are markers of poor outcomes.